HUP0402537A3 - Compositions comprising epothilones and their use for the treatment of carcinoid syndrome - Google Patents

Compositions comprising epothilones and their use for the treatment of carcinoid syndrome

Info

Publication number
HUP0402537A3
HUP0402537A3 HU0402537A HUP0402537A HUP0402537A3 HU P0402537 A3 HUP0402537 A3 HU P0402537A3 HU 0402537 A HU0402537 A HU 0402537A HU P0402537 A HUP0402537 A HU P0402537A HU P0402537 A3 HUP0402537 A3 HU P0402537A3
Authority
HU
Hungary
Prior art keywords
epothilones
compositions
treatment
carcinoid syndrome
carcinoid
Prior art date
Application number
HU0402537A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUP0402537A2 publication Critical patent/HUP0402537A2/hu
Publication of HUP0402537A3 publication Critical patent/HUP0402537A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epoxy Compounds (AREA)
HU0402537A 2001-12-13 2002-12-12 Compositions comprising epothilones and their use for the treatment of carcinoid syndrome HUP0402537A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34216701P 2001-12-13 2001-12-13
US41599002P 2002-10-04 2002-10-04
PCT/EP2002/014162 WO2003049734A1 (en) 2001-12-13 2002-12-12 Compositions comprising epothilones and their use for the treatment of carcinoid syndrome

Publications (2)

Publication Number Publication Date
HUP0402537A2 HUP0402537A2 (hu) 2005-03-29
HUP0402537A3 true HUP0402537A3 (en) 2009-01-28

Family

ID=26992855

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402537A HUP0402537A3 (en) 2001-12-13 2002-12-12 Compositions comprising epothilones and their use for the treatment of carcinoid syndrome

Country Status (22)

Country Link
US (3) US20050020647A1 (https=)
EP (1) EP1463504B1 (https=)
JP (1) JP4672257B2 (https=)
KR (1) KR101010767B1 (https=)
CN (1) CN1602192A (https=)
AT (1) ATE330602T1 (https=)
BR (1) BR0214917A (https=)
CA (1) CA2468994A1 (https=)
CY (1) CY1105459T1 (https=)
DE (1) DE60212710T2 (https=)
DK (1) DK1463504T3 (https=)
ES (1) ES2266610T3 (https=)
HU (1) HUP0402537A3 (https=)
IL (1) IL162166A0 (https=)
MX (1) MXPA04005712A (https=)
NO (1) NO332773B1 (https=)
NZ (1) NZ533378A (https=)
PL (1) PL209147B1 (https=)
PT (1) PT1463504E (https=)
RU (1) RU2341261C2 (https=)
TW (1) TWI287986B (https=)
WO (1) WO2003049734A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU2003235761A1 (en) * 2002-01-14 2003-07-24 Novartis Ag Combinations comprising epothilones and anti-metabolites
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2499682A1 (en) * 2002-10-09 2004-04-22 Kosan Biosciences, Inc. Epo d + 5-fu/gemcitabine
AU2004268377B2 (en) * 2003-09-02 2008-06-26 Novartis Ag Cancer treatment with epothilones
US20050171167A1 (en) 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
HUE071943T2 (hu) 2015-02-03 2025-10-28 Amryt Endo Inc Akromegália kezelése oktreotid orális alkalmazásával
RU2633266C2 (ru) * 2015-07-02 2017-10-11 Рауф Ашрафович Ашрафов Способ моделирования карциноидного синдрома
JP2025508846A (ja) * 2022-02-25 2025-04-10 アムリット・エンドゥ・インコーポレイテッド 疾患の治療のための経口オクトレオチド

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356270A (en) * 1977-11-08 1982-10-26 Genentech, Inc. Recombinant DNA cloning vehicle
US4318477A (en) * 1980-09-22 1982-03-09 Kerpe Stase Z Pharmaceutical package
US5753616A (en) * 1986-11-10 1998-05-19 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
DE3845000C2 (de) * 1987-07-10 1998-11-19 Novartis Ag Anwendung von Octreotid zur Behandlung von Brustkrebs
KR20000015944A (ko) * 1996-05-24 2000-03-15 팜 윌리암 엔. 신체 통로의 질병을 치료 또는 예방하기 위한조성물 및 방법
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
DK1367057T3 (da) * 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
DE19908760A1 (de) * 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
AU2001266583A1 (en) * 2000-05-26 2001-12-11 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same

Also Published As

Publication number Publication date
TWI287986B (en) 2007-10-11
PT1463504E (pt) 2006-10-31
NO332773B1 (no) 2013-01-14
IL162166A0 (en) 2005-11-20
DE60212710T2 (de) 2007-01-11
KR20040066893A (ko) 2004-07-27
HK1069983A1 (en) 2005-06-10
EP1463504A1 (en) 2004-10-06
PL369141A1 (en) 2005-04-18
TW200301113A (en) 2003-07-01
CN1602192A (zh) 2005-03-30
KR101010767B1 (ko) 2011-01-25
MXPA04005712A (es) 2004-12-06
HUP0402537A2 (hu) 2005-03-29
WO2003049734A1 (en) 2003-06-19
RU2004121687A (ru) 2005-08-10
JP4672257B2 (ja) 2011-04-20
US20050020647A1 (en) 2005-01-27
CY1105459T1 (el) 2010-04-28
ES2266610T3 (es) 2007-03-01
ATE330602T1 (de) 2006-07-15
JP2005511721A (ja) 2005-04-28
NO20042832L (no) 2004-07-05
DK1463504T3 (da) 2006-10-02
RU2341261C2 (ru) 2008-12-20
DE60212710D1 (de) 2006-08-03
US20060229345A1 (en) 2006-10-12
EP1463504B1 (en) 2006-06-21
AU2002366531A1 (en) 2003-06-23
BR0214917A (pt) 2004-11-30
CA2468994A1 (en) 2003-06-19
US20090246172A1 (en) 2009-10-01
NZ533378A (en) 2006-03-31
PL209147B1 (pl) 2011-07-29

Similar Documents

Publication Publication Date Title
HUP0401514A3 (en) Pharmaceutical compositions for the treatment of asthma
PT1757606E (pt) Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
IL158523A0 (en) Epothilone derivatives and pharmaceutical compositions containing the same
IL196301A0 (en) Medicament for the treatment of hapatitis c
PL366636A1 (en) Pyranoindazoles and their use for the treatment of glaucoma
IL157326A0 (en) Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors
HUP0402537A3 (en) Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
ZA200306082B (en) Parasiticidal compositions and methods of use
HUP0401392A3 (en) Use of composition comprising anti-hla-antibody for treatment of diseases involving prolierative immune response
HUP0600436A3 (en) Catheter composition and uses thereof
EP1472273A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
EP1455780A4 (en) NEW BENZODIFURANIMIDAZOLIN AND BENZOFURANIMIDAZOLIN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA
PT1532141E (pt) Derivados de 2-pirrolidin-2-il-[1,3,4]-oxadiazole e sua utilização como antidepressivos
AU2002337843A8 (en) Processes for the preparation of substituted isoxazoles and 2-isoxazolines
AUPR809001A0 (en) Compositions for the treatment and prevention of plant pathogens
AU7402201A (en) Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments
SI1463504T1 (sl) Sestavki, ki vkljucujejo epotilone, in njihova uporaba pri zdravljenju karcinoidnega sindroma
HUP0002154A3 (en) Use of famotidine for the preparation of pharmaceutical compositions treating depression or symptoms related with depression
EP1305017A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF SYNDROME X
EP1414427A4 (en) KAVALACTONE COMPOSITIONS AND METHODS OF USE
HU0104528D0 (en) Process for the preparation and use of biocide compositions
AU2002313019A1 (en) Compounds of the family of 3-alkyl-(4,5 dipheny-imidazol-1-yl) and their use as soothing agents
SI1392292T1 (sl) Piranoindazoli in njihova uporaba pri zdravljenjuglavkoma
AU2001219672A1 (en) Phenoxyethyl-thiourea-pyridine compounds and their use for the treatment of hiv-infections
IL136687A0 (en) Pharmaceutical composition for the treatment of multiple sclerosis

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished